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SUMMARY
Renal hypertension is one of the earliest and the most prevalent complications of pediatric chronic kid-
ney disease (CKD). Among renal patients, hypertension is frequently underdiagnosed and undertreated. 
For casual blood pressure measurement, the best method is auscultatory, while for ambulatory blood 
pressure measurement, oscillometric method is the most commonly used. Both casual and ambula-
tory blood pressure measurement provide more powerful means of diagnosing hypertension. Masked 
hypertension is a condition in which casual blood pressure is normal but ambulatory blood pressure 
is elevated. The risk of cardiovascular morbidity and mortality is higher with masked hypertension as 
compared to the controls. Children and adolescents with CKD are at high risk of cardiovascular disease 
that has been established as the leading cause of death in patients with end stage renal disease. Left 
ventricular hypertrophy remains the most thoroughly documented form of end-organ damage caused 
by hypertension in children and adolescents with CKD. Based on clear evidence on the correlation be-
tween blood pressure and cardiovascular morbidity, mortality, and renal function, renal hypertension 
must be aggressively treated. Target blood pressure for patients with renal hypertension should be at 
low normal values: <75 percentile for patients without proteinuria and <50 percentile for patients with 
proteinuria. Renin-angiotensin system antagonists are considered the first choice pharmacological op-
tion in hypertensive CKD 2-4 patients while the management of volume overload is the most important 
in dialysis patients. Successful transplantation can eliminate or significantly improve uremia-related 
cardiovascular risk factors and increase predicted life expectancy.
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INTRODUCTION
In contrast to adults, secondary forms of arterial 
hypertension predominate in infancy and child-
hood but, as adolescence approaches, there is a 
higher incidence of essential hypertension [1]. 
Renal hypertension is the most common (ap-
proximately 85%) identifiable secondary hy-
pertension in children. It is one of the earliest 
and most prevalent complications of pediatric 
chronic kidney disease (CKD). Over a half of all 
children have hypertension even in early CKD, 
increasing up to 50-75% in CKD stage 5, and 50-
78% in transplanted patients [2]. Long-standing 
and uncontrolled hypertension is associated 
with progression of CKD and development of 
early cardiomyopathy and vascular damage and 
re-modeling [3]. Aggressive treatment of hyper-
tension is necessary not just to prevent the de-
velopment of cardiovascular disorder (CVD), 
but also to improve renal survival in CKD pa-
tients. The current review focuses on the early 
identification and management of hypertensive 
disease in renal patients during childhood.
UNDERLYING DISEASE
Renal parenchymal disease
Renal hypertension occurs most frequently in 
renal parenchymal disease; chronic glomeru-
lopathy and renal scarring with or without vesi-
coureteral reflux and/or obstruction are pre-
dominant. In the ESCAPE trial, the prevalence 
of hypertension was 88% in patients with the 
acquired glomerulopathies, 38% in children 
with hypo/dysplastic kidney disorders, and 
57% in other congenital or hereditary renal 
diseases [4]. Renal scarring of reflux nephropa-
thy or obstructive uropathy also significantly 
contributes to the prevalence of pediatric renal 
hypertension. Approximately 10% of children 
with reflux nephropathy will develop hyperten-
sion, and by late adolescence, the prevalence 
will account for 18-20%; in long- term fol-
low between 30% and 40% of subjects will be 
hypertensive [5, 6]. Other causes, such as the 
polycystic kidney disease, damaged kidney be-
cause of the acute kidney injury (as in patients 
recovering from severe HUS) and renal tumors 
are important but less common.
Renovascular hypertension
Renovascular disease (RVD) occurs in ap-
proximately 10% of patients with hypertension 
in tertiary reference center [7]. Fibromuscular 
dysplasia, neurofibromatosis type I, tuberous 
sclerosis, Takayasu’s arteritis, middle aortic syn-
drome, and Williams syndrome are some of the 
conditions that result in renal arterial stenosis 
and renal ischemia [7]. It is important to diag-  
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nose RVD early, as it is potentially curable with interven-
tional treatment. Recent technological advances including 
Doppler renal ultrasound, radioisotope renogram with ACE 
inhibitors, high-resolution computed tomographic (CT) 
angiography, and magnetic resonance (MR) angiography 
have improved non-invasive investigations, but renal an-
giography is still a gold standard for diagnosis of RVD [8]. 
The treatment of children with RVD should be managed by 
a multidisciplinary team and should be based on a combi-
nation of antihypertensive drugs, angioplasty, and surgery.
HYPERTENSION IN PATIENTS WITH THE CHRONIC 
RENAL FAILURE
The prevalence of hypertension increases directly with 
the prevalence of concomitant renal failure; by the time 
CKD reaches stage 5, the majority of affected children 
have hypertension [2]. Recent ESPN/ERA-EDTA regis-
try [9] found hypertension in over two-thirds of patients 
on renal replacement therapy (RRT). Hypertension was 
more prevalent in patients under 3 years compared to 13-
17 year old, during the first compared to over 5 years of 
RRT, and in patients on hemodialysis compared to trans-
plant recipients or those on peritoneal dialysis. Over time, 
mean blood pressure (BP) decreased in both hemodialysis 
and transplant recipients patients, but not in patients on 
peritoneal dialysis [9]. Similar results were obtained in a 
cross-sectional study sample of patients on chronic dialysis 
aged 1-21 years enrolled in the North American Pediatric 
Renal Trials and Collaborative Studies registry from 1992-
2008 [10]. At 6 months after dialysis was initiated, 67.9% of 
3447 patients (65.7% on peritoneal dialysis and 34.3% on 
hemodialysis) had uncontrolled or untreated hypertension, 
and 57.8% were prescribed antihypertensive medications. 
More recent year of dialysis initiation was associated with 
higher use of antihypertensive medication and lower systo-
lic BP and diastolic BP Z-scores measured over time from 
6 months to 3 years after dialysis initiation. Other factors 
associated with higher BP included black race, glomerular 
disease, younger age, hemodialysis (systolic BP only), and 
antihypertensive use. There were significant differences in 
BP control by dialysis modality and disease etiology, with 
patients on hemodialysis or those with glomerular diseases 
having the highest percentage of uncontrolled hyperten-
sion 10]. In another cross-sectional study that included 624 
pediatric patients on chronic hemodialysis, 79% of patients 
had hypertension [11]. Hypertension was uncontrolled in 
74% of treated patients, and untreated in 21% of hyperten-
sive patients. Control of BP after kidney transplantation 
remains also sub-optimal; over 25% of patients remain hy-
pertensive 5 years following the transplantation [12].
EVALUATION OF RENAL HYPERTENSION
The same definition of hypertension is used for children 
with renal disease as for healthy ones [13]. Currently, using 
casual BP measurements and according to the criteria of 
the Fourth Report on the Diagnosis, Evaluation, and Treat-
ment of High Blood Pressure in Children and Adolescents, 
hypertension is defined as average systolic and diastolic 
BP >95th percentile for age, gender, and height measured 
on at least three separate occasions [14]. Defining hyper-
tension in the neonate is based on published norms for 
gestational and post-natal age [15, 16].
Casual BP should be measured when the patient is calm 
using validated, periodically checked and calibrated BP 
devices with the appropriately sized cuff [17]. In hemodi-
alysis patients the cuff should be applied to the non-fistula 
arm. Casual BP recordings obtained by oscillometric de-
vices have to be regularly checked by auscultatory methods 
(ideally with a mercury manometer) because, compared 
with auscultation, the oscillometric device significantly 
overestimates both systolic and diastolic BP, leading to 
frequent misclassification of BP status [18]. However, 
oscillometric method is preferred for non-invasive BP 
measurement in infants, as the Korotkoff sounds are often 
difficult to hear [19]. In addition, oscillometric method is 
preferred method for home BP monitoring. In children 
with the chronic renal failure, home BP monitoring was 
found to be superior to clinic BP measurement in predict-
ing ambulatory BP (ABPM), but neither clinic nor home 
BP monitoring detected hypertension with enough sensi-
tivity to replace ABPM [20].
ABPM has become the method of choice for diagno-
sis and therapeutic monitoring of arterial hypertension 
in pediatric and adult renal patients [21, 22]. It is with-
out observer bias and “white coat” effect. ABPM provides 
more representative observation of BP throughout day and 
night in non-medical environment. It allows quantifying 
the circadian and ultradian BP variability [23]. ABPM is 
especially helpful in hemodialysis patients because it ena-
bles better recognition of intra- and post-dialytic (particu-
lar nocturnal) BP changes when continued over 24 or 48 
h [24, 25]. Furthermore, ABPM is superior to casual BP 
concerning better correlation with target-organ damage 
such as the left ventricular hypertrophy and the ability to 
diagnose masked hypertension (i.e., normal casual BP but 
increased ambulatory daytime BP) in children with CKD 
stage 5 and after renal transplantation [26, 27]. Finally, the 
results of ABPM are more closely related to renal func-
tion in transplanted patients than the results of casual BP 
[28]. Therefore, ABPM should be performed regularly in 
all patients on RRT, at least every 6–12 months, regardless 
of casual BP values.
Together casual and ambulatory BP measurements 
provide more powerful means of diagnosing hypertension 
[17, 29]. True hypertension and true normotension are 
conditions in which casual and ABPM agree. Alternatively, 
white coat hypertension is a condition in which casual 
measurements are consistently elevated while ambulatory 
measurements are normal, and masked hypertension is 
the inverse condition in which casual measurements are 
normal but ambulatory measurements are elevated [27]. 
BP load is defined as the percentage of valid ambulatory 
BP measures above the set threshold value, such as the 95th 
percentile of BP for gender and height [30], while normal      
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nocturnal BP dipping is generally defined as nocturnal 
decline of mean systolic and diastolic ABPM level by at 
least 10%. In growth retarded CKD patients, normative 
data for casual BP should be taken for the 5th–95th height 
percentile and normative data for ABPM for the patient’s 
height regardless of the patient’s age.
CARDIOVASCULAR DISORDERS IN CHILDREN WITH 
RENAL HYPERTENSION
The cardiovascular disorder (CVD) is the main risk factor 
of morbidity and mortality in CKD patients, especially of 
those on RRT [31]. Despite decades of improvements in 
care for children with the end-stage renal disease, recent 
epidemiological studies have demonstrated highly in-
creased risk of cardiovascular mortality as the patients sur-
vive to adulthood [32, 33, 34]. The risk is sufficiently high 
as to place children with CKD in the highest American 
Heart Association cardiovascular risk category, on par with 
type 1 diabetes and familial hypercholesterolemia [35].
Four main structural abnormalities of the heart have 
been described in CKD patients: (1) left ventricle (LV) 
hypertrophy (LVH); (2) expansion of the nonvascular 
cardiac interstitium leading to intracardial fibrosis; (3) 
changes of the vascular architecture (thickening of in-
tramyocardial arterioles and reduction of capillary length 
density); and (4) myocardial calcification [36]. LVH is 
the most relevant cardiac abnormality in children with 
CKD5. Two forms of LVH may be distinguished [37]. 
Concentric (or symmetric) LVH, caused by the pressure 
overload, leads to disproportionate overgrowth of cardio-
myocytes with thickening of both interventricular septum 
and left ventricular posterior wall. Eccentric (or asym-
metric) LVH, caused mainly by volume overload, results 
primarily in dilatation of the LV chamber, and increased 
wall thickness sufficient to counterbalance the dilatation 
with predominant thickening of the interventricular 
septum. In CKD5, both forms of LVH may be present 
and have been described in dialyzed children in 70–80% 
of cases [38]. Concentric left ventricle remodeling may 
be also present in patients without LVH. Although LVH 
is an adaptive response to chronic pressure and volume 
overload (allowing maintenance of systolic function), its 
persistence may become detrimental because it impairs 
diastolic compliance and reduces coronary perfusion re-
serve. Reduced diastolic filling is closely associated with 
LVH and increased stiffness of the LV chamber owing to 
collagen accumulation.
In parallel with cardiac abnormalities, hypertension 
induces alterations in the structure and function of the 
arterial tree manifested as coronary calcifications and wall 
thickening of the carotid arteries. It can be in the form of 
Mönckeberg sclerosis that is a particular type of arterial 
medial calcification; in addition, patients with CKD can 
develop atherosclerotic vascular disease – a form of inti-
mal calcification [39]. The key CVD-related risk factors 
include “traditional” ones (hypertension, dyslipidemia, in-
sulin resistance, increased lipoprotein (a), obesity as well 
as malnutrition) and uremia-related factors of which the 
most common in children are deregulation of the calcium, 
phosphors-parathormone (Ca-P-PTH) and vitamin D axis 
[39]. Once vascular damage and calcification begin, they 
progress inexorably in uremic patients and may be only 
partially reversed after successful renal transplantation. 
Given the known prognostic significance of cardiovas-
cular lesions and hypertensive end organ damage, early 
and regularly monitoring cardiac function and geometry 
(echocardiography) is required even in the absence of 
any clinical signs of CVD. Additional methods to identify 
increased intravascular volume include bioimpedance, 
sonography of the inferior vena cava diameter and deter-
mination of the ANP in plasma, as well as monitoring of 
hematocrit. Until data from longitudinal follow-up studies 
become available, serial carotid artery intima media thick-
ness, pulse wave velocity and multi-slice CT for coronary 
artery calcification would be useful only for research pur-
pose or in CKD patients at high risk for CVD.
TREATMENT OF RENAL HYPERTENSION
Therapeutic management of hypertension reduces mortal-
ity and sequels of life-threatening conditions. It reduces 
left ventricular hypertrophy and also the rate of progres-
sion to end-stage renal disease [40]. The results of ES-
CAPE trial showed that low normal BP (<75 percentile 
in CKD patients without proteinuria and <50 percentile 
in those with proteinuria) improved renal survival and 
contributed to regression of CVD [41].
If an identified treatable cause of hypertension was de-
tected (such as renal artery stenosis, vasculitis, glomeru-
lonephritis), the primary disease, leading to BP elevation, 
should be treated [42, 43]. Otherwise, adequate pharmaco-
therapy along with strict volume control and other lifestyle 
modifications should be helpful in BP normalization. RAS 
antagonists are considered the first choice pharmacologi-
cal option in patients with hypertensive and/or proteinuric 
CKD. However, the use of more than one drug with dif-
ferent mechanism of action is often required for effective 
lowering of blood pressure. In an individualized approach, 
the initial antihypertensive drug is chosen on the basis of 
presumed mechanism and severity of hypertension; con-
comitant diseases and therapies; availability of appropriate 
formulations (e.g., suspension and dosage choices); and, 
when available, pediatric safety, pharmacokinetics, and 
efficacy data. The choice of additional antihypertensive 
drugs in children with CKD is largely arbitrary [41]. Di-
hydropyridine calcium channel blockers have no antipro-
teinuric effect and may actually promote proteinuria and 
more rapid CKD progression, while non-dihydropyridine 
calcium channel blockers (diltiazem and verapamil) are 
antiproteinuric and therefore potentially renoprotec-
tive, but have weaker effect on blood pressure. The use 
of β-receptor blockers seems rational in view of the sym-
pathetic over-activation in CKD. Newer β-blockers, e.g., 
carvedilol, have significantly higher antiproteinuric effect 
than atenolol in comparable blood pressure reduction.  
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Once blood pressure is controlled for 6–12 months and 
target-organ damage has regressed or resolved, an attempt 
to decrease the dosage or number of antihypertensive 
medications should be considered.
Having in mind that hypervolemia is the main con-
tributing risk factor of hypertension in uremic patients, 
an appropriate initial management of hypertension in a 
dialyzed child will be gradual fluid extraction to control 
BP and achieve an ideal “dry weight,” i.e., the weight at 
which most of the excess fluid has been extracted. Anti-
hypertensive drugs should be used in dialyzed children 
only if BP remained elevated, despite seemingly adequate 
volume and sodium control. The target “dry weight” has 
to be periodically reassessed and adjusted according to 
the child’s growth and changes in muscle or fat mass. The 
dialysis prescription often has to be modified for better 
control of BP, e.g., switching to longer, more frequent (e.g., 
daily) or nocturnal hemodialysis sessions or by minimiz-
ing the sodium content in food and dialysate fluid. Nev-
ertheless, long dialysis vintage has been implicated in all 
studies as a significant and independent risk factor of CVD 
development. Therefore, every effort must be made to pre-
pare a child for preemptive renal transplantation whenever 
feasible.
CONCLUSION
Hypertension is one of the most common cardiovascular 
risk factors in children with CKD, but it is also often un-
derdiagnosed and undertreated. A careful measurement of 
blood pressure should result in early detection of hyper-
tension in patients with CKD. The choice of antihyperten-
sive treatment should be tailored to the main contributing 
risk factor of hypertension.
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КРАТАК САДРЖАЈ
Ре  нал  на хи  пер  тен  зи  ја је јед  на од нај  ра  ни  јих и нај  че  шћих 
ком  пли  ка  ци  ја хро  нич  не бо  ле  сти бу  бре  га (ХББ) код де  це, 
али че  сто оста  је не  пре  по  зна  та и не  ле  че  на. За кла  сич  но, 
ин  тер  ми  тент  но ме  ре  ње крв  ног при  ти  ска нај  бо  ља је аускул-
та  тор  на ме  то  да, док се за ам  бу  ла  тор  но ме  ре  ње нај  че  шће 
при  ме  њу  је осци  ло  ме  триј  ска ме  то  да. За  јед  нич  ка при  ме  на 
обе ове ме  то  де по  бољ  ша  ва ди  јаг  но  сти  ко  ва  ње и кла  си  фи  ка-
ци  ју хи  пер  тен  зи  је код де  це са ХББ. Ма  ски  ра  на хи  пер  тен  зи  ја 
је ста  ње по  ви  ше  ног ам  бу  ла  тор  ног и нор  мал  ног кла  сич  но 
из  ме  ре  ног крв  ног при  ти  ска. Ри  зик од кар  ди  о  ва  ску  лар  ног 
мор  би  ди  те  та и мор  та  ли  те  та је ве  ћи код ма  ски  ра  не хи  пер-
тен  зи  је не  го код нор  мо  тен  зив  не де  це. Де  ца и адо  ле  сцен  ти 
са ХББ су у ви  со  ком ри  зи  ку за кар  ди  о  ва  ску  лар  не бо  ле  сти, 
ко  је су глав  ни узрок смр  ти у тер  ми  нал  ном ста  ди  ју  му ХББ. 
Хи  пер  тро  фи  ја ле  вог ср  ца је нај  бо  ље до  ка  за  но хи  пер  тен-
зив  но ор  ган  ско оште  ће  ње код де  це и адо  ле  сце  на  та са ХББ. 
На осно  ву ја  сних до  ка  за за ко  ре  ла  ци  ју хи  пер  тен  зи  је с кар-
ди  о  ва  ску  лар  ним мор  би  ди  те  том, мор  та  ли  те  том и функ  ци  јом 
бу  бре  га, ре  нал  ну хи  пер  тен  зи  ју тре  ба ле  чи  ти агре  сив  ним 
ме  то  да  ма. Циљ  ни крв  ни при  ти  сак код де  це са ХББ је на ни-
воу ни  ских нор  мал  них вред  но  сти: <75 пер  цен  ти  ла код де  це 
без про  те  и  ну  ри  је, од  но  сно <50 пер  цен  ти  ла код бо  ле  сни  ка 
с про  те  и  ну  ри  јом. Код обо  ле  лих од ХББ ста  ди  јума 2–4 лек 
из  бо  ра за хи  пер  тен  зи  ју су ан  та  го  ни  сти си  сте  ма ре  нин-ан-
ги  о  тен  зин, а код бо  ле  сни  ка у тер  ми  нал  ном ста  ди  ју  му глав-
на те  ра  пиј  ска ме  ра је от  кла  ња  ње хи  пер  во  ле  ми  је. Успе  шна 
тран  сплан  та  ци  ја бу  бре  га от  кла  ња или по  бољ  ша  ва уре  мич-
не фак  то  ре ри  зи  ка за кар  ди  о  ва  ску  лар  на обо  ље  ња, чи  ме се 
по  бољ  ша  ва пре  жи  вља  ва  ње бо  ле  сни  ка.
Кључ  не ре  чи: ин  су  фи  ци  јен  ци  ја бу  бре  га; кар  ди  о  ва  ску  лар  не 
бо  ле  сти; хи  пер  тро  фи  ја ле  вог ср  ца; де  ца
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